Avneet Kaur, M.D.

Degrees

• 2015, Doctor of Medicine, Ross University School of Medicine

Fellowship

• 2022, Transplant Infectious Disease, University of California Los Angeles, Los Angeles, California
• 2021, Infectious Disease, SUNY Downstate Medical Center, Brooklyn, New York

Residency

• 2019, University of Maryland Capital Region Medical Center, Largo, Maryland

Professional Experience

• 2022–present Assistant Clinical Professor, Division of Infectious Diseases, Department of Medicine, City of Hope, Duarte, California

Research Experience

Lead researcher in quality improvement project regarding patients receiving Bamlanivimab in mild SARS-CoV2 illness, 1/2021 to present

• We included a group of 50 patients that received Bamlanivimab for mild COVID illness in our outpatient and inpatient setting. We reviewed charts and interviewed patients to compare their symptoms prior to and after receiving the monoclonal antibody. Also, we investigated to evaluate if any of these patients were hospitalized after receiving the monoclonal antibody.

Co-researcher in presenting the long-term effects of SARS-CoV2 in immunocompetent, immunocompromised patients as well as patients with various underlying comorbidities, 7/2020 to present

• We included 500 patients at Brooklyn VA hospital who were diagnosed with SARS-CoV2 infection from March through April 2020. Several of these patients had underlying comorbidities and behavioral health issues prior to being diagnosed. We differentiated them based on mild, moderate and severe COVID illness and followed them up at 30, 60, 90 and 180 days. We are analyzing the long-term impact of SARS-Co2 patients in these selected patients and how it increased health care burden and future hospitalizations.

Future co-author of book chapter on Anthrax sponsored by Elsevier

• We are writing a chapter to be published in a book in 2022, which will include history, epidemiology, global outbreaks in the last 10 years, clinical presentation, diagnosis, treatment, prevention, prophylaxis, bioterrorism and nonbioterrorism implications and future research on anthrax.

Lead researcher in internal medicine adult health immunization QI project, 1 to 8/2017

• We conducted a three-month retrospective QI project among adults aged 21-65 in Cheverly Clinic. We reviewed charts of 100 patients to evaluate if they adequately received all vaccinations needed as per their age, comorbidities, annual visits prophylaxis. We educated patients about herd immunity and preventive vaccinations like Hep A vaccine and various travel vaccines.

Lead researcher in lung screening QI project, 7/2016 to 08/2018

• We conducted this project to screen high-risk patients for lung cancer with low dose CT scan. We reviewed charts of 270 patients, and 21 were selected to be enrolled in screening process as per guidelines from USPSTF.

Researcher in internal medicine glycemic control of diabetes mellitus in a resident clinic, 8 to 11/2016

• In this three-month quality improvement research project, we reviewed charts of 104 patients who did not meet glycemic targets. We escalated the diabetic therapy in order to ensure HbA1c target.